Piroxicam/2-hydroxypropyl-β-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique

Journal of Pharmaceutical Sciences

Volumn 98, Issue 2, 2009, Pages 665-675

  Zhang, Xingwang ^a   Wu, Danni ^a   Lai, Jie ^b   Lu, Yi ^a   Yin, Zongning ^b   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

2 hydroxypropyl cyclodextrin; Coating; Dissolution; Fluid bed; Inclusion complex; Physical characterization; Piroxicam; Powder technology

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CAVASOL; PIROXICAM; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ALCOHOL; BETA CYCLODEXTRIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM BETA CYCLODEXTRIN; PIROXICAM-BETA-CYCLODEXTRIN; SOLVENT;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; FLUIDIZED BED; INFRARED SPECTROSCOPY; RAMAN SPECTROMETRY; X RAY DIFFRACTION; AEROSOL; CHEMISTRY; DRUG DOSAGE FORM; EVALUATION; FEASIBILITY STUDY; KINETICS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICS; POWDER DIFFRACTION; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

AEROSOLS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DOSAGE FORMS; ETHANOL; FEASIBILITY STUDIES; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; PIROXICAM; POWDER DIFFRACTION; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 59149106998     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21453     Document Type: Article

References (24)

1. Basawy SIF, Ghorab MM, Adeyeye CM. 1996. Characterization and bioavailability of danazolhydroxypropyl β-cyclodextrin coprecipitates. Int J Pharm 128:45-54.
2. Zheng Y, Haworth IS, Zuo Z, Chow MS, Chow AH. 2005. Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes. J Pharm Sci 94:1079-1089.
3. Mura P, Bettinetti GP, Cirri M, Maestrelli F, Sorrenti M, Catenacci L. 2005. Solid-state characterization and dissolution properties of Naproxen-Arginine-Hydroxypropyl-β-cyclodextrin ternary system. Eur J Pharm Biopharm 59:99-106.
4. Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
5. Loftsson T, Duchêne D. 2007. Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1-11.
6. Zoppetti G, Puppini N, Ospitali F, Fini A. 2007. Solid state characterization of progesterone in a freeze dried 1:2 progesterone/HPBCD mixture. J Pharm Sci 96:1729-1736.
7. de Araú jo MV, Vieira EK, Lázaro GS, de Souza Conegero L, Ferreira OP, Almeida LS, Barreto LS, da Costa NB Jr, Gimenez IF. 2007. Inclusion complexes of pyrimethamine in 2-hydroxypropyl-β-cyclodextrin: Characterization, phase solubility and molecular modeling. Bioorg Med Chem 15:5752-5759.
8. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, Hwang SJ. 2007. Preparation and characterization of simvastatin/hydroxypropyl-β- cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 66:413-421.
9. Latrofa A, Trapani G, Franco M, Serra M, Muggironi M, Fanizzi FP, Cutrignelli A, Liso G. 2001. Complexation of phenytoin with some hydrophilic cyclodextrins: Effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice. Eur J Pharm Biopharm 52:65-73.
10. Pose-Vilarnovo B, Perdomo-López I, Echezarreta-López M, Schroth-Pardo P, Estrada E, Torres-Labandeira JJ. 2001. Improvement of water solubility of sulfamethizole through its complexation with β- and hydroxypropyl-β-cyclodextrin Characterization of the interaction in solution and in solid state. Eur J Pharm Sci 13:325-331.
11. Lin SY, Kao YH. 1989. Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Int J Pharm 56:249-259.
12. Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W. 2007. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a onestep fluid-bed coating technique. Powder Technol 182:72-80.
13. Zhang X, Sun N, Wu B, Lu Y, Guan T, Wu W. 2007. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technol 182:480-485.
14. Rozou S, Voulgari A, Antoniadou-Vyza E. 2004. The effect of pH dependent molecular conformation and dimerization phenomena of piroxicam on the drug: Cyclodextrin complex stoichiometry and its chromatographic behaviour. A new specific HPLC method for piroxicam: Cyclodextrin formulations. Eur J Pharm Sci 21:661-669.
15. Van Hees T, Piel G, de Hassonville SH, Evrard B, Delattre L. 2002. Determination of the free/included piroxicam ratio in cyclodextrin complexes: Comparison between UV spectrophotometry and differential scanning calorimetry. Eur J Pharm Sci 15:347-353.
16. Zhou YH, Zhang GM, Wang ZR, Wang HY, Dong C, Shuang SM. 2006. The interaction of piroxicam with neutral (HP-β-CD) and anionically charged (SBE-β-CD) β-cyclodextrin. J Incl Phenom Macro 56:215-220.
17. Basan H, Góǧer NG, Ertaş N, Orbey MT. 2001. Quantitative determination of piroxicam in a new formulation (piroxicam-β-cyclodextrin) by derivative UV spectrophotometric method and HPLC. J Pharm Biomed Anal 26:171-178.
18. Pande GS, Shangraw RF. 1995. Characterization of β-cyclodextrin for direct compression tableting: II. The role of moisture in the compactibility of β-cyclodextrin. Int J Pharm 124:231-239.
19. Pande GS, Shangraw RF. 1994. Characterization of β-cyclodextrin for direct compression tableting. Int J Pharm 101:71-80.
20. Pillay V, Fassihi R. 1998. Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J Control Release 55:45-55.
21. Polli JE, Rekhi GS, Augsburger LL, Shah VP. 1997. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86:690-700.
22. Choudhury S, Nelson KF. 1992. Improvement or oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-β-cyclodextrin. Int J Pharm 85:175-180.
23. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. 1999. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 181:143-151.
24. Redenti E, Peveri T, Zanol M, Ventura P, Gnappi G, Montenero A. 1996. A study on the differentiation between amorphous piroxicam: β-cyclodextrin complex and a mixture of the amorphous components two amorphous components. Int J Pharm 129:289-294.